SLC5A2 and cardiovascular disorder: Further prospective studies could also explore whether newer anti-diabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is), that can lower the risk of cardiovascular disease, might have an impact upon the circulating levels of the biomarkers studied here.